AllianceBernstein’s Aquestive Therapeutics AQST Stock Holding History

AllianceBernstein’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Buy	95,640 +3,650	+4%	+$15.4K	﹤0.01%	2851
2026 Q1	$594K	Hold	91,990	–	–	﹤0.01%	2549
2025 Q4	$594K	Buy	91,990 +3,900	+4%	+$24.3K	﹤0.01%	2568
2025 Q3	$492K	Hold	88,090	–	–	﹤0.01%	2688
2025 Q2	$292K	Buy	88,090 +46,800	+113%	+$134K	﹤0.01%	2924
2025 Q1	$120K	Hold	41,290	–	–	﹤0.01%	3038
2024 Q4	$147K	Hold	41,290	–	–	﹤0.01%	3077
2024 Q3	$206K	Buy	41,290 +10	+0%	+$39	﹤0.01%	3035
2024 Q2	$107K	Buy	+41,280	New	+$138K	﹤0.01%	3116
2021 Q2	–	Sell	-15,800	Closed	-$82K	–	3324
2021 Q1	$82K	Hold	15,800	–	–	﹤0.01%	3176
2020 Q4	$85K	Hold	15,800	–	–	﹤0.01%	3120
2020 Q3	$77K	Hold	15,800	–	–	﹤0.01%	3098
2020 Q2	$77K	Buy	+15,800	New	+$72.7K	﹤0.01%	3125
2019 Q2	–	Sell	-316,464	Closed	-$2.19M	–	3143
2019 Q1	$2.19M	Sell	316,464 -334,751	-51%	-$2.35M	﹤0.01%	1841
2018 Q4	$4.1M	Sell	651,215 -166,777	-20%	-$2.11M	﹤0.01%	1403
2018 Q3	$14.3M	Buy	+817,992	New	+$13.5M	0.01%	875

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

AllianceBernstein's AQST Position: Q2 2026 in Review

AllianceBernstein increased its Aquestive Therapeutics (AQST) stake by 4% in Q2 2026, buying an estimated $15.4K and bringing the position to 95,640 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

AllianceBernstein first reported a position in AQST in Q3 2018 and has held it in 16 quarters since. The position peaked at $14.3M in Q3 2018. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

AllianceBernstein held 95,640 shares of Aquestive Therapeutics worth $397K as of Q2 2026.
AllianceBernstein bought 3,650 Aquestive Therapeutics shares in Q2 2026, an estimated $15.4K.
Aquestive Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2851 holding.
AllianceBernstein first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 16 quarters since.
AllianceBernstein's Aquestive Therapeutics position peaked at $14.3M in Q3 2018.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.